Liminatus Pharma, Inc. Class A Common Stock Cash Flow-to-Debt Ratio
Liminatus Pharma, Inc. Class A Common Stock cash flow-to-debt ratio. Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a Cash Flow-to-Debt Ratio of -0.31x as of June 2026, meaning its operating cash flow of $-970.00K could theoretically repay 0% of its total liabilities ($3.10 Million) in one year. Check cash flow quality index of Liminatus Pharma, Inc. Class A Common St to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
Cash flow-to-debt ratio of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. Historical debt coverage capacity for Liminatus Pharma, Inc. Class A Common Stock across 5 annual periods. Also explore Liminatus Pharma, Inc. Class A Common St (LIMN) net asset momentum to track the company's year-over-year net asset growth rate.
Liminatus Pharma, Inc. Class A Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
Liminatus Pharma, Inc. Class A Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Liminatus Pharma, Inc. Class A Common Stock. For the full cash flow conversion analysis, see Liminatus Pharma, Inc. Class A Common St operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.96x | $-9.96 Million | $10.33 Million | ▼ -480.7% |
| 2024 | -0.17x | $-3.11 Million | $18.70 Million | ▲ +24.5% |
| 2023 | -0.22x | $-3.35 Million | $15.19 Million | ▼ -259.6% |
| 2022 | -0.06x | $-869.00K | $14.19 Million | ▼ -8.6% |
| 2021 | -0.06x | $-1.22 Million | $21.57 Million | — |